FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Washington, D.C. 20049

STATEMENT	OF CHANGES IN	N BENEFICIAL	OWNERSHIP

l	OMB APPRO	VAL
	OMB Number:	3235-0287
l	Estimated average burd	en
l	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* PFREUNDSCHUH PETER P.						2. Issuer Name and Ticker or Trading Symbol UroGen Pharma Ltd. [URGN]										5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O UROGEN PHARMA LTD. 499 PARK AVENUE					3. Date of Earliest Transaction (Month/Day/Year) 08/20/2019											X Officer (give title Other (specify below) Chief Financial Officer					
(Street) NEW YORK CITY 10022				4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)									Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(5)		(Zip)	n Deriv	rative		curiti	ios Ac		ired [)ici	nosed (of or B	one	ficial	ly Own	ed				
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transac Date (Month/Da			action	ction 2A. Deemed Execution Date,		, [3. 4. Secur Transaction Dispose Code (Instr. 5)		4. Securi	ities Acquired (A) d Of (D) (Instr. 3, 4		(A) or	5. Am Secur Bener Owne	ount of ities icially d Following	Fori	m: Direct	7. Nature of Indirect Beneficial Ownership				
									Code	,	Amount	(A) (D)	or	Price		ted action(s) 3 and 4)			(Instr. 4)		
Ordinary Shares 08/20/				/2019	2019			M		4,167	7 A	1	(1)	4,167			D				
Ordinary Shares 08/20/2				/2019	2019 s 1,416 D \$				\$33.0	3.07 2,751 ⁽²⁾ D											
		Т	able II -									sed of, onverti				Owne	d				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transa Code (8)		n of		Exp	6. Date Exercisa Expiration Date (Month/Day/Yea			7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)			8. Price of Derivativ Security (Instr. 5)		e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Dat Exe	te ercisable		xpiration ate	Title	or No of	umber						
Restricted Stock Units	(1)	08/20/2019			М			4,167		(3)		(3)	Ordinary Shares	4	,167	\$0.00	8,33	3	D		

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
- $2. \ Represents \ shares \ sold \ to \ satisfy \ withholding \ tax \ obligations \ upon \ the \ settlement \ of \ restricted \ stock \ units.$
- 3. The reporting person was granted restricted stock units ("RSUs") on July 19, 2018 representing 12,500 ordinary shares. 33.33% of the RSUs will vest on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.

Remarks:

/s/ Peter Pfreundschuh, Attorney-in-Fact

08/21/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.